China Gaucher Disease Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.7% during the forecast period.
Gaucher disease is a rare, inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain fats (lipids), specifically the glycolipid glucocerebroside, throughout the body especially within the bone marrow, spleen and liver. The prevalence of Gaucher disease in China is about 1:200,000 to 1:500,000 persons. Incidence rate is 1.24 per 100,000 persons in China.
China is a growing market for Gaucher disease due to factors such as increase in China’s incidence rate (1.24 per 100,000 persons) and prevalence rate (1:200,000 to 1:500,000 persons). Other factors that contribute to the growth of the market are awareness campaigns by various organizations and affordable reimbursement scenarios for treatment.
However, there are some restraining factors for growth of the Gaucher disease therapeutics market in China such as high cost of medicines, misdiagnosis (in 2019 61.9% of Gaucher disease patients have experienced misdiagnosis, and 27.9% of patients need 1-5 years to be diagnosed).